Vanda Pharmaceuticals Inc (VNDA)
5.02
+0.13
(+2.66%)
USD |
NASDAQ |
Nov 07, 16:00
5.015
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Revenue (TTM): 182.02M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 182.02M |
| March 31, 2024 | 177.60M |
| December 31, 2023 | 192.64M |
| September 30, 2023 | 211.85M |
| June 30, 2023 | 238.35M |
| March 31, 2023 | 256.69M |
| December 31, 2022 | 254.38M |
| September 30, 2022 | 257.92M |
| June 30, 2022 | 262.70M |
| March 31, 2022 | 266.20M |
| December 31, 2021 | 268.68M |
| September 30, 2021 | 268.32M |
| June 30, 2021 | 258.53M |
| March 31, 2021 | 252.84M |
| December 31, 2020 | 248.17M |
| September 30, 2020 | 241.44M |
| June 30, 2020 | 240.62M |
| March 31, 2020 | 237.48M |
| December 31, 2019 | 227.19M |
| September 30, 2019 | 219.30M |
| June 30, 2019 | 208.95M |
| March 31, 2019 | 197.24M |
| December 31, 2018 | 193.12M |
| September 30, 2018 | 184.35M |
| June 30, 2018 | 176.55M |
| Date | Value |
|---|---|
| March 31, 2018 | 171.26M |
| December 31, 2017 | 165.08M |
| September 30, 2017 | 159.05M |
| June 30, 2017 | 156.20M |
| March 31, 2017 | 150.17M |
| December 31, 2016 | 146.02M |
| September 30, 2016 | 139.62M |
| June 30, 2016 | 129.48M |
| March 31, 2016 | 121.04M |
| December 31, 2015 | 109.92M |
| September 30, 2015 | 93.44M |
| June 30, 2015 | 79.88M |
| March 31, 2015 | 63.16M |
| December 31, 2014 | 50.16M |
| September 30, 2014 | 43.57M |
| June 30, 2014 | 37.50M |
| March 31, 2014 | 34.95M |
| December 31, 2013 | 33.88M |
| September 30, 2013 | 33.02M |
| June 30, 2013 | 32.60M |
| March 31, 2013 | 32.65M |
| December 31, 2012 | 32.73M |
| September 30, 2012 | 33.18M |
| June 30, 2012 | 32.86M |
| March 31, 2012 | 31.91M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
177.60M
Minimum
Mar 2024
268.68M
Maximum
Dec 2021
239.14M
Average
248.17M
Median
Dec 2020
Revenue (TTM) Benchmarks
| Zevra Therapeutics Inc | 23.99M |
| Edgewise Therapeutics Inc | -- |
| NovaBay Pharmaceuticals Inc | 12.02M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |